✦ LIBER ✦

Serum I131 fractionation in metastatic carcinoma of the thyroid. The fate of endogenous radiothyroxine after I131 therapy

✍ Scribed by Manuel Tubis; Franz K. Bauer; H. Bruce Thomas; Vivian E. Anderson

Publisher: John Wiley and Sons
Year: 1955
Tongue: English
Weight: 624 KB
Volume: 8
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(1955)8:6<1115::aid-cncr2820080604>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioiodine I-131 therapy in the managem

Radioiodine I-131 therapy in the management of thyroid cancer. A prospective study

✍ G. T. Krishnamurthy; W. H. Blahd 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

Prognostic value of the 131I whole-body

Prognostic value of the 131I whole-body scan in postsurgical therapy for differentiated thyroid cancer

✍ Alberto Pupi; Antonio Castagnoli; Aldo Morotti; Giuseppe La Cava; Ugo Meldolesi 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB 👁 2 views

Phase I/II trial of 131I-MN-14 F(ab)2 an

Phase I/II trial of 131I-MN-14 F(ab)2 anti–carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

✍ Malik E. Juweid; George Hajjar; Lawrence C. Swayne; Robert M. Sharkey; Samer Sul 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 1 views

## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab

Prospective randomized clinical trial to

Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma

✍ Adam Taube; Göran Lundell 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

outcome of 87 patients with gallbladder carcinoma (GBC) who underwent surgery. The authors concluded that surgical resection provides significantly better survival than a bypass procedure or exploratory laparotomy alone. Because radical tumor resection may significantly improve survival as compared

Prospective randomized clinical trial to

Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma

✍ Chandrasekhar Bal; Ajit K. Padhy; Suman Jana; Gauri S. Pant; Amar K. Basu 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

## BACKGROUND. Radioiodine has been used for more than a half-century to ablate thyroid remnants following thyroid surgery, but a single optimal dose has not been established. We designed a prospective randomized trial to determine the optimal dose of 13'1 for remnant ablation. METHODS. Using a si